Aliskiren 3.125 mini-tablets

Phase 2

Novartis AG (NVS)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

5

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Hypertension

Clinical Trial

NCT00834041

Last updated: 1/10/2026

Regulatory Approvals

EMA

8/22/2007

Rasilez

Treatment of essential hypertension.

View on EMA

EMA8/22/2007

Sprimeo

Treatment of essential hypertension.

View on EMA

EMA8/22/2007

Riprazo

Treatment of essential hypertension.

View on EMA

EMA8/22/2007

Enviage

Treatment of essential hypertension

View on EMA

EMA8/22/2007

Tekturna

Treatment of essential hypertension

View on EMA

Developer

NVS

Novartis AG

Biotechnology•Europe•NYSE

Related Pipeline

FamciclovirPhase 3

Genital Herpes

Crizanlizumab (SEG101)Phase 3

Sickle Cell Disease (SCD)

DabrafenibPhase 3

Melanoma

secukinumab low dosePhase 3

Moderate to Severe Chronic Plaque-type Psoriasis

PimecrolimusPhase 3

Atopic Dermatitis

View full pipeline